Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidyl-prolyl cis-trans isomerase A-like 4G (PPIAL4G) is a predicted enzyme of the peptidyl-prolyl cis-trans isomerase (PPIase) family, potentially involved in catalyzing the cis-trans isomerization of proline imidic peptide bonds, a key reaction in protein folding[3]. There are no confirmed therapeutic roles, disease associations, or known drug interactions for PPIAL4G. The information appears possibly incorrect or ambiguous, as most research and database entries focus on more established cyclophilin family members, such as PPIA (Cyclophilin A)[1][3], or on the related PPIAL4A gene[5]. No clear evidence supports PPIAL4G as a validated drug target, biomarker, or therapeutic receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase A-like 4G (PPIAL4G).